RNAi Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board
TL;DR
Dr. Zamore's appointment enhances TransCode's RNA-targeted cancer therapy programs, giving a strategic edge in the field.
TransCode focuses on treating metastatic disease through intelligent RNA therapeutics delivery with TTX nanoparticle platform.
TransCode's innovative RNA therapeutics offer hope for better cancer treatment by targeting specific genetic markers of metastatic tumors.
Dr. Zamore's foundational work in RNA biology adds a fascinating dimension to TransCode's cutting-edge cancer therapy research.
Found this article helpful?
Share it with your network and spread the knowledge!
TransCode Therapeutics has appointed Dr. Phillip D. Zamore to its Scientific Advisory Board, a strategic move that could significantly bolster the company's RNA-targeted cancer therapy research. Dr. Zamore, a leading expert in RNA interference (RNAi) and co-founder of Alnylam Pharmaceuticals, brings extensive experience in RNA biology and gene silencing mechanisms.
As Chair of the RNA Therapeutics Institute at UMass Chan Medical School, Zamore's election to the National Academy of Sciences underscores his scientific credibility. His expertise could be particularly valuable to TransCode's ongoing efforts to develop innovative RNA therapeutics for treating metastatic cancers.
The company's lead therapeutic candidate, TTX-MC138, focuses on treating metastatic tumors that overexpress microRNA-10b, a specific biomarker associated with cancer metastasis. Zamore's deep understanding of RNA mechanisms could potentially accelerate the development and effectiveness of TransCode's therapeutic approaches.
By adding such a prominent scientific figure to its advisory board, TransCode demonstrates a commitment to advancing cutting-edge oncology research and developing novel RNA-based treatment strategies that could potentially transform cancer therapy.
Curated from InvestorBrandNetwork (IBN)
